Prothena Corporation plc Ordinary Shares
PRTAStock
$8.47+35.53%52W
Market Cap$441.34M
P/E—
Div yield—
Beta-0.39
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.13%
Price vs S&P 500 (4W)1.09%
VGM Score58.60
Market Capitalization$441.34M
Earnings Surprise History
Q1 260.61est. -0.36
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.75
3.75
3.75
3.75
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PRTAProthena Corporation plc Ordinary Shares | B | B | C | $8.47 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Prothena is a late-stage clinical biotechnology company developing treatments for neurodegenerative and amyloid diseases using its proprietary CYTOPE platform, which targets intracellular disease pathways in the brain and body. The company's pipeline includes Prasinezumab for Parkinson's disease, Coramitug for ATTR amyloidosis, and partnered programs targeting Alzheimer's disease and ALS. Prothena combines wholly-owned and partnered assets to address protein-dysregulation disorders with significant unmet medical needs.